Table 1.

Health state transitions, per annual cycle

	Method failure (p)	Discontinuation 1st year (p)	Discontinuation subsequent year (p)	Market weight
LNG-IUS 13.5mg	0.00331	0.20002	0.05	1.000
SARC4	0.0870	0.3409	0.05	1.000
COC	0.09003	0.33003	0.05	0.789
Vaginal ring	0.09003	0.33003	0.05	0.082
Patch	0.09003	0.33003	0.05	0.021
Injectable	0.06003	0.44003	0.05	0.108
Subsequent method4	0.1443	0.3048	0.05	1.000
LNG-IUS 13.5mg	0.00331	0.20003	0.05	0.020
OCs	0.09003	0.33003	0.05	0.370
Ring	0.09003	0.33003	0.05	0.039
Patch	0.09003	0.33003	0.05	0.010
Injection	0.06003	0.44003	0.05	0.051
Implant	0.00053	0.16003	0.05	0.010
IUD	0.00803	0.22003	0.05	0.030
LNG-IUS 20mcg	0.00203	0.20003	0.05	0.030
Barrier Methods	0.18003	0.55503	0.05	0.218
Tubal ligation	0.00503	0.00003	0.05	0.046
Tubal occlusion	0.00503	0.00003	0.05	0.046
No method	0.46005	0.05006	0.05	0.129

¹Published source [12].

²Assumption – set equal to LNG-IUS 20 mcg/24 hours (total content 52mg) discontinuation rate [8]

³Published source [8].

⁴Estimated for base case age group of 20–29 years as a weighted average – weights based on NSFG [7] (see ‘Market Weight’ column).

⁵Published source [16].

⁶Assumption.